436 related articles for article (PubMed ID: 24998329)
1. Macitentan for the treatment of pulmonary arterial hypertension.
DuBrock HM; Channick RN
Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
[TBL] [Abstract][Full Text] [Related]
2. Macitentan for the treatment of pulmonary arterial hypertension.
Kholdani CA; Fares WH; Trow TK
Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292
[TBL] [Abstract][Full Text] [Related]
3. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
Belge C; Delcroix M
Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
[TBL] [Abstract][Full Text] [Related]
5. Development of macitentan for the treatment of pulmonary arterial hypertension.
Selej M; Romero AJ; Channick RN; Clozel M
Ann N Y Acad Sci; 2015 Nov; 1358():68-81. PubMed ID: 26291180
[TBL] [Abstract][Full Text] [Related]
6. Macitentan: A Review in Pulmonary Arterial Hypertension.
Keating GM
Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996
[TBL] [Abstract][Full Text] [Related]
7. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
[TBL] [Abstract][Full Text] [Related]
8. Macitentan for the treatment of pulmonary arterial hypertension.
Sood N
Expert Opin Pharmacother; 2014 Dec; 15(18):2733-9. PubMed ID: 25385427
[TBL] [Abstract][Full Text] [Related]
9. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
[TBL] [Abstract][Full Text] [Related]
11. Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension.
Clarke M; Walter C; Agarwal R; Kanwar M; Benza RL
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):415-21. PubMed ID: 24851934
[TBL] [Abstract][Full Text] [Related]
12. Macitentan for the treatment of pulmonary arterial hypertension.
Hong IS; Coe HV; Catanzaro LM
Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
[TBL] [Abstract][Full Text] [Related]
13. Macitentan for the treatment of pulmonary arterial hypertension.
Spikes L; Williamson T; Satterwhite L
Drugs Today (Barc); 2014 Jun; 50(6):401-6. PubMed ID: 24983588
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Sidharta PN; Krähenbühl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
[TBL] [Abstract][Full Text] [Related]
15. Macitentan: a review of its use in patients with pulmonary arterial hypertension.
Dhillon S
Drugs; 2014 Sep; 74(13):1495-507. PubMed ID: 25060980
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
[TBL] [Abstract][Full Text] [Related]
17. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension.
Martynyuk TV; Nakonechnikov SN; Chazova IY
Ter Arkh; 2018 Apr; 90(4):72-80. PubMed ID: 30701878
[TBL] [Abstract][Full Text] [Related]
18. Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension.
Monaco TJ; Davila CD
Drug Des Devel Ther; 2016; 10():1675-82. PubMed ID: 27274200
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension.
Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kimura T; Kondo T; Matsushita M; Minamino T; Nakanishi N; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Sasayama S
Circ J; 2016 May; 80(6):1478-83. PubMed ID: 27180890
[TBL] [Abstract][Full Text] [Related]
20. Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series.
Mathijssen H; Huitema MP; Bakker ALM; Mager JJ; Snijder RJ; Grutters JC; Post MC
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(1):74-78. PubMed ID: 33093771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
